NasdaqGS:IMCRBiotechs
Should Immunocore’s Higher Revenue and Narrower Loss in 2025 Require Action From Immunocore Holdings (IMCR) Investors?
In late February 2026, Immunocore Holdings plc reported fourth-quarter revenue of US$104.48 million and a quarterly net loss of US$30.06 million, while full-year revenue reached US$400.02 million with the annual net loss narrowing to US$35.51 million versus the prior year.
The results underscore Immunocore’s ability to grow sales and reduce full-year losses even as it continues to invest heavily in advancing its ImmTAX-based pipeline beyond its lead product.
We’ll now examine how this...